309 related articles for article (PubMed ID: 22457519)
41. Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.
Chan YH; Teo TH; Utt A; Tan JJ; Amrun SN; Abu Bakar F; Yee WX; Becht E; Lee CY; Lee B; Rajarethinam R; Newell E; Merits A; Carissimo G; Lum FM; Ng LF
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31015278
[TBL] [Abstract][Full Text] [Related]
42. Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.
Gromowski GD; Firestone CY; Whitehead SS
J Virol; 2015 Jun; 89(12):6328-37. PubMed ID: 25855730
[TBL] [Abstract][Full Text] [Related]
43. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
[TBL] [Abstract][Full Text] [Related]
44. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
45. Enhanced Molecular Surveillance of Chikungunya Virus.
Fischer C; de Lamballerie X; Drexler JF
mSphere; 2019 Jul; 4(4):. PubMed ID: 31270168
[TBL] [Abstract][Full Text] [Related]
46. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
47. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence.
Tsetsarkin KA; Weaver SC
PLoS Pathog; 2011 Dec; 7(12):e1002412. PubMed ID: 22174678
[TBL] [Abstract][Full Text] [Related]
48. P108 and T109 on E2 Glycoprotein Domain I Are Critical for the Adaptation of Classical Swine Fever Virus to Rabbits but Not for Virulence in Pigs.
Xie L; Han Y; Ma Y; Yuan M; Li W; Li LF; Li M; Sun Y; Luo Y; Li S; Hu S; Li Y; Qiu HJ
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581110
[TBL] [Abstract][Full Text] [Related]
49. High-Titer Self-Propagating Capsidless Chikungunya Virus Generated in Vero Cells as a Strategy for Alphavirus Vaccine Development.
Zhang YN; Zhang ZR; Li N; Pei XR; Li XD; Deng CL; Ye HQ; Zhang B
J Virol; 2022 Mar; 96(6):e0148021. PubMed ID: 35107379
[TBL] [Abstract][Full Text] [Related]
50. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.
Albariño CG; Bird BH; Chakrabarti AK; Dodd KA; Flint M; Bergeron E; White DM; Nichol ST
J Virol; 2011 Oct; 85(19):10404-8. PubMed ID: 21795336
[TBL] [Abstract][Full Text] [Related]
51. Chikungunya virus arthritis in adult wild-type mice.
Gardner J; Anraku I; Le TT; Larcher T; Major L; Roques P; Schroder WA; Higgs S; Suhrbier A
J Virol; 2010 Aug; 84(16):8021-32. PubMed ID: 20519386
[TBL] [Abstract][Full Text] [Related]
52. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes.
Tsetsarkin KA; Chen R; Leal G; Forrester N; Higgs S; Huang J; Weaver SC
Proc Natl Acad Sci U S A; 2011 May; 108(19):7872-7. PubMed ID: 21518887
[TBL] [Abstract][Full Text] [Related]
53. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
Basu R; Zhai L; Rosso B; Tumban E
Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
[TBL] [Abstract][Full Text] [Related]
54. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
55. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.
Roy CJ; Adams AP; Wang E; Plante K; Gorchakov R; Seymour RL; Vinet-Oliphant H; Weaver SC
J Infect Dis; 2014 Jun; 209(12):1891-9. PubMed ID: 24403555
[TBL] [Abstract][Full Text] [Related]
56. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
[TBL] [Abstract][Full Text] [Related]
57. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus.
Rohatgi A; Corbo JC; Monte K; Higgs S; Vanlandingham DL; Kardon G; Lenschow DJ
J Virol; 2014 Mar; 88(5):2414-25. PubMed ID: 24335291
[TBL] [Abstract][Full Text] [Related]
58. Mutations in the carboxyl terminal region of E2 glycoprotein of classical swine fever virus are responsible for viral attenuation in swine.
Risatti GR; Holinka LG; Fernandez Sainz I; Carrillo C; Kutish GF; Lu Z; Zhu J; Rock DL; Borca MV
Virology; 2007 Aug; 364(2):371-82. PubMed ID: 17418362
[TBL] [Abstract][Full Text] [Related]
59. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.
Albulescu IC; White-Scholten L; Tas A; Hoornweg TE; Ferla S; Kovacikova K; Smit JM; Brancale A; Snijder EJ; van Hemert MJ
Viruses; 2020 Mar; 12(3):. PubMed ID: 32191995
[TBL] [Abstract][Full Text] [Related]
60. Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.
Dupuis-Maguiraga L; Noret M; Brun S; Le Grand R; Gras G; Roques P
PLoS Negl Trop Dis; 2012; 6(3):e1446. PubMed ID: 22479654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
